Orasure technologies CEO purchases $247,377 in common stock

Published 28/02/2025, 03:18
Orasure technologies CEO purchases $247,377 in common stock

Carrie Eglinton Manner, the President and CEO of OraSure Technologies Inc. (NASDAQ:OSUR), recently acquired 78,625 shares of the company’s common stock. The purchase comes as the stock trades near its 52-week low of $2.69, with InvestingPro analysis indicating the stock is currently undervalued. The shares were purchased on February 27, 2025, in the open market at a weighted average price of $3.1463 per share, with prices ranging from $3.05 to $3.27. This transaction amounted to a total value of approximately $247,377. Following this purchase, Eglinton Manner now holds 1,259,664 shares of OraSure Technologies directly. Analysts maintain price targets between $4 and $6, suggesting potential upside. For deeper insights into insider trading patterns and comprehensive analysis, check out the detailed OraSure Technologies Pro Research Report, available exclusively on InvestingPro.

In other recent news, OraSure Technologies reported its fourth-quarter 2024 earnings, surpassing revenue forecasts with $37.45 million, slightly above the expected $36.72 million. Despite the revenue beat, the company’s gross margin of 40.1% fell short of the consensus expectation of 43.4%, attributed to reduced COVID-19 testing revenue and changes in international sales mix. Citi analyst Patrick Donnelly responded to these results by lowering the price target for OraSure to $6 from $9, while maintaining a Buy rating, reflecting concerns over future revenue uncertainties. The company has provided guidance for the first quarter of 2025, projecting revenues between $27.5 million and $31.5 million, with core business expected to generate most of this figure. OraSure’s management highlighted ongoing challenges, including uncertainties in U.S. funding, which have led some customers to scale back their activities. Additionally, OraSure ended the quarter with a strong cash position of $268 million and aims to achieve a 50% gross margin through operational efficiencies. The company also noted strategic acquisitions, such as Sherlock Biosciences, and product innovations as key drivers for future growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.